نتائج البحث - Teresa Alonso‐Gordoa

تنقيح النتائج
  1. 1
    GEP–NETs UPDATE: Biotherapy for neuroendocrine tumours

    GEP–NETs UPDATE: Biotherapy for neuroendocrine tumours حسب Teresa Alonso‐Gordoa, Jaume Capdevila, Enrique Grande

    منشور في 2014
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Advances in thyroid cancer treatment: latest evidence and clinical potential

    Advances in thyroid cancer treatment: latest evidence and clinical potential حسب Teresa Alonso‐Gordoa, Juan J. Díez, Manuel Durán, Enrique Grande

    منشور في 2014
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Targeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys”

    Targeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys” حسب Teresa Alonso‐Gordoa, Laura García‐Bermejo, Enrique Grande, Pilar Garrido, Alfredo Carrato, Javier Molina‐Cerrillo

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma

    Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma حسب Pablo Álvarez Ballesteros, Jesús Chamorro, María San Román, Javier Pozas, V. Gómez Dos Santos, Álvaro Ruiz Granados, Enrique Grande, Teresa Alonso‐Gordoa, Javier Molina‐Cerrillo

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    BRAF Mutated Colorectal Cancer: New Treatment Approaches

    BRAF Mutated Colorectal Cancer: New Treatment Approaches حسب Javier Molina‐Cerrillo, María San Román, Javier Pozas, Teresa Alonso‐Gordoa, Miguel Pozas, Elisa Conde, Marta Rosas Cancio-Suárez, Enrique Grande, Laura García‐Bermejo, Alfredo Carrato

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Tyrosine Kinase Receptors in Oncology

    Tyrosine Kinase Receptors in Oncology حسب Jorge Esteban-Villarrubia, J.J. Soto Castillo, Javier Pozas, María San Román, Inmaculada Orejana-Martín, Javier Torres-Jiménez, Alfredo Carrato, Teresa Alonso‐Gordoa, Javier Molina‐Cerrillo

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors

    Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors حسب Sandip Pravin Patel, Teresa Alonso‐Gordoa, Susana Banerjee, Ding Wang, Jarushka Naidoo, Nathan Standifer, Doug Palmer, Lin‐Yang Cheng, Panagiotis Kourtesis, Maria Libera Ascierto, Mayukh Das, Jennifer R. Diamond, Matthew D. Hellmann, Benedito A. Carneiro

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer

    A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer حسب Teresa Alonso‐Gordoa, Michael Goodman, Christof Vulsteke, Guilhem Roubaud, J. Zhang, Mamta Parikh, Josep M. Piulats, A. Ázaro, Gary D. James, Riccardo Cavazzina, Eric T. Gangl, Jeff Thompson, Gayle P. Pouliot, Rakesh Kumar, Christopher J. Sweeney

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)

    The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407) حسب Enrique Grande, Àlex Teulé, Teresa Alonso‐Gordoa, Paula Jiménez‐Fonseca, Marta Benavent, Jaume Capdevila, Ana Custodio, Ruth Vera, Javier Munárriz, Adelaida La Casta, Juan J. Díez, Pablo Gajate, Javier Molina‐Cerrillo, Ignacio Matos, Eva Cristóbal, J.C. Ruffinelli, José Palacios, Rocio García‐Carbonero

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma

    Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma حسب Yohann Loriot, Cora N. Sternberg, Daniel Castellano, Sjoukje F. Oosting, Herlinde Dumez, Robert Huddart, Karina Vianna, Teresa Alonso Gordoa, Iwona Skoneczna, André P. Fay, Franco Nolé, Francesco Massari, Birutė Brasiūnienė, Pablo Maroto, Simon Fear, Flavia Di Nucci, Sabine de Ducla, Ernest Choy

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

    Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE) حسب Enrique Grande, Jaume Capdevila, Daniel Castellano, Àlex Teulé, Ignacio Durán, Josep Fuster, Isabel Sevilla, P. Escudero, Javier Sastre, Jesús García-Donás, Oriol Casanovas, Julie Earl, Luís Ortega, María Apellániz-Ruiz, Cristina Rodríguez‐Antona, Teresa Alonso‐Gordoa, Juan J. Díez, Alfredo Carrato, Rocio García‐Carbonero

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma

    Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcin... حسب Yohann Loriot, Cora N. Sternberg, D. Castellano Gauna, Herlinde Dumez, Robert Huddart, Karina Vianna, Teresa Alonso Gordoa, Iwona Skoneczna, AP Fay, Cosimo Sacco, Franco Nolè, Francesco Massari, Birute Brasiūnienė, Pablo Maroto, Sjoukje F. Oosting, Simon Fear, Flavia Di Nucci, Sabine de Ducla, Ernest Choy

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study

    Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Adva... حسب Viktor Grünwald, Thomas Powles, Evgeny Kopyltsov, Vadim Kozlov, Teresa Alonso‐Gordoa, Masatoshi Eto, Thomas E. Hutson, Robert J. Motzer, Eric Winquist, Pablo Maroto, Bhumsuk Keam, Giuseppe Procopio, Shirley Wong, Bohuslav Melichar, Frédéric Rolland, Mototsugu Oya, Karla Rodriguez-Lopez, Kenichi Saito, Jodi A. McKenzie, Camillo Porta

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)

    1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or l... حسب Jaume Capdevila, Àlex Teulé, Carlos López, Rocio García‐Carbonero, Marta Benavent, Ana Custodio, Antonio Cubillo, Vicente Alonso, Teresa Alonso Gordoa, Alberto Carmona‐Bayonas, Guillermo Crespo, Montserrat Blanco-Codesido, Paula Jiménez‐Fonseca, A. Viúdez, Adelaida La Casta Muñoa, Isabel Sevilla, Marta Llanos, Ángel Segura, Jorge Hernando-Cubero, José Luís Manzano

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)

    Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter... حسب María Carmen Riesco Martínez, Jaume Capdevila, Vicente Alonso, Paula Jiménez‐Fonseca, Àlex Teulé, Enrique Grande, Isabel Sevilla, Marta Benavent, Teresa Alonso‐Gordoa, Ana Custodio, Beatriz Antón-Pascual, Jorge Hernando, Eduardo Polo, Oscar Alfredo Castillo Trujillo, Arantza Lamas‐Paz, Ana Teijo, Yolanda Rodriguez-Gil, Beatriz Soldevilla, Rocio García‐Carbonero

    منشور في 2024
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

    Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin حسب Jaume Capdevila, Jorge Hernando, Àlex Teulé, Carlos López, Rocio García‐Carbonero, Marta Benavent, Ana Custodio, Alejandro García‐Álvarez, Antonio Cubillo, Vicente Alonso, Alberto Carmona‐Bayonas, Teresa Alonso‐Gordoa, Guillermo Crespo, Paula Jiménez‐Fonseca, M. Blanco, A. Viúdez, Adelaida La Casta, Isabel Sevilla, Ángel Segura, Marta Llanos, Stefania Landolfi, Paolo Nucíforo, José Luís Manzano

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

    Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma حسب David F. McDermott, Jae‐Lyun Lee, Georg A. Bjarnason, James Larkin, Rustem Gafanov, Mark D. Kochenderfer, Niels Viggo Jensen, Frede Donskov, Jahangeer Malik, Alexandr Poprach, Scott S. Tykodi, Teresa Alonso‐Gordoa, Daniel C. Cho, Poul Geertsen, Miguel Á. Climent Durán, Christopher DiSimone, Rachel Kloss Silverman, Rodolfo F. Perini, Charles Schloss, Michael B. Atkins

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

    Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study حسب Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca, Ángela Lamarca, Jorge Barriuso, Ángel Castaño, Marta Benavent, Vicente Alonso, María Carmen Riesco Martínez, Teresa Alonso‐Gordoa, Ana Custodio, Manuel Sánchez Cánovas, Jorge Hernando Cubero, Carlos López, Adelaida La Casta, Ana Fernández Montés, Mónica Marazuela, Guillermo Crespo, P. Escudero, José Ángel Díaz, E. Feliciangeli, Javier Gállego, Marta Llanos, Ángel Segura, F Vilardell, Juan Carlos Percovich, Enrique Grande, Jaume Capdevila, Juan W. Valle, Rocio García‐Carbonero

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study

    Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study حسب Camillo Porta, Francesco Massari, Tarek Taha, Enrique Grande, María T. Bourlon, Ravindran Kanesvaran, Umberto Basso, Javier Molina‐Cerrillo, Teresa Alonso‐Gordoa, Zin Myint, Giuseppe Fornarini, Thomas Büttner, Se Hoon Park, Yüksel Ürün, Ugo De Giorgi, Renate Pichler, Pasquale Rescigno, Tomáš Büchler, Hana Študentová, Bohuslav Melichar, Jawaher Ansari, Veronica Mollica, Jakub Kucharz, Mimma Rizzo, Alessandro Rizzo, Ray Manneh Kopp, Sebastiano Buti, Fernando Sabino Marques Monteiro, Andrey Soares, Aristotelis Bamias, Matteo Santoni

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

    Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma حسب Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frédéric Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: